| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
Authors' Affiliations: 1 Endocrine Cancer Group, Section of Surgical and Translational Research, Glasgow University and 2 Department of Pathology, Glasgow Royal Infirmary, Glasgow, United Kingdom
Requests for reprints: John Bartlett, Endocrine Cancer Group Section of Surgical and Translational Research, Division of Cancer Sciences and Molecular Pathology, University Department of Surgery, Level II Queen Elizabeth Building, Glasgow Royal Infirmary, Glasgow, G31 2ER, United Kingdom. Phone: 141-211-5436; Fax: 141-211-5432; E-mail: J.M.Bartlett{at}clinmed.gla.ac.uk.
Purpose: Resistance to tamoxifen is linked to overexpression of HER2, and aromatase inhibitors show particular benefit in progesterone receptor (PR)–negative patients. We previously reported reduced survival in patients overexpressing HER1, HER2, and HER3. We now show that both HER1-3 and PR status predicts for early relapse in estrogen receptor (ER)–positive tamoxifen-treated breast cancer patients.
Experimental Design: Tissue microarray technology was used to analyze 402 ER-positive tamoxifen-treated patients. Immunohistochemistry using epidermal growth factor receptor, HER2, HER3, HER4, and PR antibodies was done. Kaplan-Meier life table and Cox Regression analysis (log-rank testing of differences in breast cancer–related relapse on tamoxifen) was done.
Results: HER1-3 (but not HER4) overexpression predicted for early relapse on tamoxifen (P = 0.0060). PR-negative cases were also significantly more likely to relapse while on tamoxifen (P= 0.017). HER1-3-positive and/or PR-negative patients combined as a "high-risk" group were significantly more likely to relapse on tamoxifen in univariate (P < 0.0001) and Cox's multivariate analysis (P = 0.0069). However, this applied to early relapse on tamoxifen only, as any disease relapse after 3 years of tamoxifen was unrelated to PR/HER status.
Conclusions: We show that HER1-3 and PR status can identify time-dependent de novo tamoxifen resistance with risk declining markedly after 3 years of tamoxifen treatment. These results parallel data from the ATAC and Intergroup Exemastane Study trials which suggest that whereas PR-negative patients derive greater benefit from initial aromatase inhibitor treatment, PR status has no effect on response when given as delayed treatment to those disease free on tamoxifen after 3 years.
This article has been cited by other articles:
|
|
 |
|
  G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance Endocr. Rev., April 1, 2008; 29(2): 217 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dowsett, C. Allred, J. Knox, E. Quinn, J. Salter, C. Wale, J. Cuzick, J. Houghton, N. Williams, E. Mallon, et al. Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial J. Clin. Oncol., March 1, 2008; 26(7): 1059 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Massarweh, C. K. Osborne, C. J. Creighton, L. Qin, A. Tsimelzon, S. Huang, H. Weiss, M. Rimawi, and R. Schiff Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function Cancer Res., February 1, 2008; 68(3): 826 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M.S. Bartlett, I. O. Ellis, M. Dowsett, E. A. Mallon, D. A. Cameron, S. Johnston, E. Hall, R. A'Hern, C. Peckitt, J. M. Bliss, et al. Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4423 - 4430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes Clin. Cancer Res., May 15, 2007; 13(10): 2831 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kirkegaard, L. M. McGlynn, F. M. Campbell, S. Muller, S. M. Tovey, B. Dunne, K. V. Nielsen, T. G. Cooke, and J. M.S. Bartlett Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor-Positive Tumors of Tamoxifen-Treated Breast Cancer Patients Clin. Cancer Res., March 1, 2007; 13(5): 1405 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Bates, S. B. Fox, C. Han, R. D. Leek, J. F. Garcia, A. L. Harris, and A. H. Banham Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse J. Clin. Oncol., December 1, 2006; 24(34): 5373 - 5380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hiscox, L Morgan, T. Green, and R. I Nicholson Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S53 - S59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Ponzone, F Montemurro, F Maggiorotto, C Robba, D Gregori, M. Jacomuzzi, F Kubatzki, D Marenco, A Dominguez, N Biglia, et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer Ann. Onc., November 1, 2006; 17(11): 1631 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Tanner, D. Hasenclever, K. Stern, W. Schormann, M. Bezler, M. Hermes, M. Brulport, A. Bauer, I. B. Schiffer, S. Gebhard, et al. ErbB-3 Predicts Survival in Ovarian Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4317 - 4323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kim, M. Kaneko, K. Arihiro, M. Emi, K. Tanabe, S. Murakami, A. Osaki, and K. Inai Extranuclear expression of hormone receptors in primary breast cancer Ann. Onc., August 1, 2006; 17(8): 1213 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dowsett, J. Houghton, C. Iden, J. Salter, J. Farndon, R. A'Hern, R. Sainsbury, and M. Baum Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status Ann. Onc., May 1, 2006; 17(5): 818 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Edwards, P. Traynor, A. F. Munro, C. F. Pirret, B. Dunne, and J. M.S. Bartlett The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer Clin. Cancer Res., January 1, 2006; 12(1): 123 - 130. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
